Infinity Pharmaceuticals, Inc. (INFI)
Pre-market:
| Previous close | 0.5373 |
| Open | 0.5200 |
| Bid | 0.5700 x 1300 |
| Ask | 0.6000 x 800 |
| Day's range | 0.5200 - 0.5765 |
| 52-week range | 0.4600 - 3.8900 |
| Volume | |
| Avg. volume | 756,506 |
| Market cap | 49.802M |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5300 |
| Earnings date | 25 Jul 2022 - 29 Jul 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.21 |
- Zacks
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass., May 03, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2022 financial results and provided a corporate update.
- Business Wire
Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., April 26, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022.
